Purpose: Recurrent bacterial cystitis is a common infection in women and there are concerns about its antibiotic therapy. Platelet rich plasma has antimicrobial and tissue repairing effects. We investigated the effect of platelet rich plasma as an intravesical therapy to prevent recurrence of bacterial cystitis.
Materials and Methods: Thirty women with a history of recurrent bacterial cystitis were randomly assigned into two groups: 1) platelet rich plasma and 2) control groups. The first group received 10 mL of platelet rich plasma with intravesical instillation plus 40 mL of normal saline. The control group only received 50 mL of normal saline. We did the instillation once a week for four weeks in both groups. We followed up the participants two and 12 months after the last instillation with a questionnaire (the international consultation on incontinence questionnaire in overactive bladder) and result of their urine culture.
Results: A significant decrease was observed in the number of bacterial cystitis recurrences in the platelet rich plasma group compared to the control group 12 months after the instillation (4 vs. 1, P = 0.004). Also, there was a significant improvement in the questionnaire’s score two (3.6 ± 2.58 vs. 0.66 ± 1.63, P = 0.002) and 12 months (3.4 ± 2.77 vs. 0.006 ± 1.83, P < 0.001) after instillation in the platelet rich plasma group compared to control group. There was no adverse effect 12 months after instillation.
Conclusion: Platelet rich plasma can significantly decrease the recurrence of bacterial cystitis up to a year after instillation without any side effect.
TM H. A prospective study for risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335:468.
Foxman B. Urinary tract infection syndromes: ocuurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1-13.
Hoberman Aea. antimicrobial prophilaxis for childeren with vesicoureteral reflux. N Engl J Med. 2014;370:2367-76.
Kudinha Tea. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J Clin Microbiol. 2013;51:3270-6.
Spellberg Bea. Novel approaches are needed to develop tomorrows antibacterial therapies. Am J Respir Crit Care Med. 2015;191:135-40.
Bent S NB, Simel DL, et al. Dose this woman have an acute urinary tract infection? JAMA. 2002;287:2701-10.
Gupta K HT, Roberts PL, et al. Patient-initiated treatment of recurrent urinary tract infection in women. Ann Intern Med. 2001;135:9-16.
Hannan TJea. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616-48.
Mysorekar IUaH, S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA. 2006;103:14170-5.
Mulvey MAea. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69:4572-9.
Schilling JDea. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun. 2002;70(7042-7049):7042.
Chan KY TW. Growth factors concentrate and the use there of. US Patent. 2015;20:300.
MR. Y. The role of platelets in antimicrobial host defense. Clinical infectious diseases. 1997(951-68):951.
O. L. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood. 2000;96:2664-72.
Yeaman MR PS, Norman D, Bayer A. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infection and immunity. 1992;60:1202-9.
Yeaman MR IA, Edwards J, Bayer A, Ghannoum M. Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro. Antimicrobial agents and chemotherapy. 1993;37:546-53.
Brubaker LaW, A. The urinary microbiota: a paradigm shift for bladder disorders? Cuee Opin Obstet Gynecol. 2016;28(407-412):407.
RE M. platelet rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62:489-96.
Man D PH, Winland-Brown JE. the use of autologous platelet-rich plasma (platele gel) and autologous platelet poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg. 2001;107:229-37.
Dönmez M.İ. Inci K ZN, Dogan H.S, Ergen A. the effect of intravesical instillation of platelet rich plasma (PRP) in interstitial cystitis model. Eur Urol Suppl. 2014;13:461.
Donmez Mi IK, Zeybek ND, Dogan HS, Ergen A. The early histological effects of intravesical instillation of platelet-rich plasma in cystitis models Int Neurourol J. 2016;20:188-96.
Lara Paro dias ACMl, Bruno B. Volpe, Marcela Duran, Sofia E.M. Galdames , Luiz A.AB. Ferreira, Nelson Duran, Wagner J.Favaro. Effect of intravesical therapy with platelet-rich plasma (PRP) and Bacillus calmette-Guerin (BCG) in non-muscle invasive bladder cancer. Tissue and Cell. 2018;52:17-27.
constantinides C MT, Nikolopoulos P, Stanitsas A, Haritopoulos K, Giannopoulos A. prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU int. 2004;93:1262-6.
Lipovac M KC, Reithmayr F, Verhoever HC, Huber JC, Imhof M. prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Genaecol Obstet. 2007;96:192-5.
Damiano R QG, Bava I. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59:645-51.
Davide De Vita SG. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012;23:1707-13.
Dutta S, Lane F. intravesical instillations for the treatment of refractory recurrent urinary tract infections. Ther Adv Urol. 2018;10:157-63.